Compare AGRO & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGRO | STOK |
|---|---|---|
| Founded | 2002 | 2014 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2011 | 2019 |
| Metric | AGRO | STOK |
|---|---|---|
| Price | $9.36 | $31.23 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $12.80 | ★ $39.20 |
| AVG Volume (30 Days) | ★ 903.4K | 544.1K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.43% | N/A |
| EPS Growth | N/A | ★ 92.73 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $184,420,000.00 |
| Revenue This Year | $45.90 | N/A |
| Revenue Next Year | N/A | $77.49 |
| P/E Ratio | $37.52 | ★ N/A |
| Revenue Growth | N/A | ★ 404.50 |
| 52 Week Low | $6.89 | $11.17 |
| 52 Week High | $15.89 | $40.22 |
| Indicator | AGRO | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 26.42 | 53.99 |
| Support Level | $7.50 | $30.34 |
| Resistance Level | $13.86 | $35.11 |
| Average True Range (ATR) | 0.51 | 1.43 |
| MACD | -0.23 | 0.32 |
| Stochastic Oscillator | 8.49 | 72.64 |
Adecoagro SA is a Luxembourg-based agricultural company. It is involved in a wide range of businesses, including farming crops and other agricultural products, dairy operations sugar, ethanol, energy production, and land transformation. The group operates in two lines of business, namely, Farming and Sugar, Ethanol and Energy. The Farming is further comprised of three reportable segments: Crops, Rice and Dairy. Sugar, Ethanol and Energy Segment, consists of cultivating sugarcane, which is processed in owned sugar mills, transformed into ethanol, sugar and electricity, in addition to biomethane and then marketed.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.